Top 5 Botox Companies
.png)
Published: July 2024
According to a study conducted by the International Society of Aesthetic Plastic Surgery (ISAPS), in 2022, Botulinum toxin was the most popular minimally invasive medical aesthetic procedure with over nine million procedures performed worldwide.We analyzed around 25 botox companies that are engaged in offering botox injections. In this article, discover five top Botox companies and their capabilities in this industry.
Botox is a toxin produced by a bacterium, Clostridium botulinum. This treatment is primarily used on the face to weaken and smoothen muscles, preventing muscle movement and thereby eliminating wrinkles on the face. The treatment usually doesn’t require the patient to be anesthetized. The results of the procedure can last for about 3-4 months. Currently, many botox companies are focusing on meeting the rise in demand for botox treatment. The cost of the treatment usually ranges from USD 400-500, making it a cost-efficient alternative as compared to surgical approaches while providing immediate results. The global botox market is projected to grow at a CAGR of around 10% till 2035, offering significant opportunities for botox companies.
In recent years, several factors have contributed towards transforming the position of botox companies. The primary advantage of opting for any medical aesthetic procedure is the improvement of one’s physical attributes. Such treatment procedures can be applied to any body part, resulting in more youthful, revitalized, and nourished skin. Medical aesthetics products and devices offer various health benefits. For instance, botox helps in limiting sweating and migraines. Physical appearance can significantly impact a person’s confidence in certain cases. These treatments can improve facial features and physique, enabling patients to feel more comfortable and confident in their own skin. The reasonable cost and long-lasting benefits of such treatments make them a suitable and low maintenance option for the patients. It is worth mentioning that the rising adoption of these solutions has resulted in significant uplift in the investment activity in this sector.
In fact, injectables, such as botox are expected to make significant contributions to the total revenue generation potential in this market. Moreover, the growing desire for a youthful, healthy and attractive appearance has driven the demand for procedures, such as botox, dermal fillers, liposuction and hair transplantation. Additionally, the non-invasive nature of these procedures, along with the benefits associated with them, such as fewer complications, less expenditure and quick recovery has garnered significant interest from industry stakeholders. Furthermore, the growing awareness, celebrity endorsements, and effective marketing strategies help to deal with the restrictions associated with aesthetic procedures. It is interesting to note that COVID-19 pandemic has also contributed to the increased demand for these treatments. According to the American Academy of Facial Plastic and Reconstructive Surgery, the pandemic has led to a 10% increase in the number of cosmetic surgeries. In fact, the Aesthetic Plastic Surgery National Databank reports that Botox injections have increased by 54% and filler treatments are up by 75%, since 2019. This can be attributed to the shift in the global work culture, with more people frequently working from their homes and attending online meetings. While most of the online applications provide options to apply various filters and effects, platforms, such as Zoom doesn’t offer any such functionalities. This self-consciousness among people, popularly termed as “Zoom Effect” has led to an increased interest in medical aesthetic procedures.
Roots Analysis has conducted an exhaustive study on Botox Market featuring the current market landscape and future opportunity for the companies developing botox injections, over a span of 12 years.
Table of Contents
Below, we have listed (in alphabetical order), the top five botox companies.
- Allergan Aesthetics
- Croma Pharma
- Galderma
- PharmaResearch
- Revance Therapeutics
Interested in exploring all 25+ Botox Companies and their recent initiatives?
Discover Below the Details on 5 Top Botox Companies
Let us deep dive to understand the activity of the 5 top botox companies (shortlisted on the basis of their employee size; more than 200 employees) in the botox market. It is essential to note that the selection of top players can differ substantially according to the defined criteria.
Allergan Aesthetics is Facing Competition With the Entry of Revance Therapeutics’ Daxxify; Allergan is Working to Expand the Indications Coverage
1. Allergan Aesthetics
Allergan Aesthetics specializes in finding solutions to signs of aging by offering a broad range of soft tissue fillers and injectables. In addition, the company offers neurotoxins, non-invasive body contouring devices and products related to plastic surgery, regenerative medicine and topical skincare. It is worth highlighting that, in May 2023, the firm has received FDA approval for Skinvive (hyaluronic acid intradermal microdroplet injection) to improve skin smoothness of the cheeks in adults, above the age of 21.
Allergan Aesthetics: Company Details
| Key Parameters | Description |
| Company Logo |  |
| Year of Establisment | 2015 |
| Number of Employees | 1,001-5,000 |
| Headquarter |  |
Allergan Aesthetics: Medical Aesthetics Portfolio
| Key Parameters | Description |
| Type of Products / Devices Offered |
|
| Application Area |
|
| Type of Procedure |
|
| End User | Hospitals / Clinics / Medical Spas |
Recent Developments:
AbbVie, the parent company of Allergan Aesthetics, is evaluating the use of Botox in new cosmetic indications. In September 2023, the company announced results from a phase 3 clinical trial for Botox in platysma prominence, a cosmetic condition related to aging. AbbVie plans to file for FDA approval in the near future.
Further details on recent initiatives taken by Allergan Aesthetics as well as other botox companies have been provided in detail in the report.
Croma Pharma is Expanding the Availability of Letybo, With Phased Launch of the Botox Product in Additional European Countries
2. Croma Pharma
Founded by Gerhard and Karin Prinz, Croma Pharma is a pharmaceutical company specializing in the development and manufacturing of minimally invasive medical aesthetic treatments. The company’s botox product, Letybo, has been developed by South Korea based Hugel, Inc. and was licensed by Croma for commercialization in Europe. Croma Pharma launched its botox product Letybo in 11 European markets in 2022.
In addition, Croma Pharma also manufactures hyaluronic acid syringes with high-quality standards. It is interesting to note that, in 2018, the firm opened a manufacturing facility (which spans an area of 2,200 sq m) to meet the growing global demand of hyaluronic acid fillers. Further, in 2017, Croma’s novel syringe received the renowned international IF design award.
Croma Pharma: Company Overview
| Key Parameters | Description |
| Company Logo |  |
| Year of Establisment | 1976 |
| Number of Employees | 501-1,000 |
| Headquarter |  |
Croma Pharma: Medical Aesthetics Portfolio
| Key Parameters | Description |
| Type of Products / Devices Offered |
|
| Application Area |
|
| Type of Procedure |
|
| End User | Hospitals / Clinics / Medical Spas |
Recent Developments:
In May 2023, Croma Pharma announced the approval of Letybo in 12 additional markets in the region. Additionally, in March 2024, Hugel America, a joint venture between Hugel Inc. and Croma Pharma received FDA approval for use of Letybo for treatment of moderate to severe frown lines in adults, and the product is expected to launch in the US in 2024.
Further details on recent initiatives taken by Croma Pharma as well as other botox companies have been provided in detail in the report.
Galderma, With its Growing Revenues and a Strong Aesthetics Injectables Market Presence Has Shown Intent to Raise Funds Through a Swiss IPO
3. Galderma
Galderma is a European pharmaceutical company specializing in the development of skincare and therapeutic dermatology. Additionally, the company has a broad portfolio of medical aesthetics, prescription medicines and consumer care products for the treatment of various skin conditions. It is worth mentioning that the firm has variety of products intended for facial treatment of dynamic wrinkles, static wrinkles and correction of asymmetries.
Further, the company is actively putting efforts into R&D, in order to advance their growing pipeline of neuromodulators, dermal fillers and biostimulators. In fact, the company is currently investigating RelabotulinumtoxinA, a next-generation, ready-to-use liquid formulation of botulinum toxin type A in phase III clinical studies, intended for the treatment of glabellar lines and lateral canthal lines. In addition, in June 2023, the firm received FDA approval for Restylane Eyelight (Hyaluronic acid filler) for the treatment of undereye hollows.
Galderma: Company Overview
| Key Parameters | Description |
| Company Logo |  |
| Year of Establisment | 1981 |
| Number of Employees | 5,001-10,000 |
| Headquarter |  |
Galderma: Medical Aesthetics Portfolio
| Key Parameters | Description |
| Type of Products / Devices Offered |
|
| Application Area | Skin Tightening |
| Type of Procedure |
|
| End User | Hospitals / Clinics / Medical Spas |
Recent Developments:
In March 2024, Galderma made clear its intent to raise $2.3 billion through IPO on the Swiss Exchange. The company has tasted success in the aesthetics injectables market with several approved products and more in clinical trials.
Further details on recent initiatives taken by Galderma as well as other botox companies have been provided in detail in the report.
PharmaResearch has Developed DNA Optimization Technology (DOT) with Registered Patent Along the Korea’s Marine Resources
4. PharmaResearch
PharmaResearch is a biopharmaceutical firm with a vision on the development of regenerative medicine. Their products are based on natural derivative substances developed using patented DNA optimization technology. The company is conducting multiple research projects with various pharmaceutical firms as well as research institutes in the US and European countries. The company is planning to continue focusing on regenerative medicine as well as anti-aging products.
PharmaResearch: Company Overview
| Key Parameters | Description |
| Company Logo |  |
| Year of Establisment | 1993 |
| Number of Employees | 201-500 |
| Headquarter |  |
PharmaResearch: Medical Aesthetics Portfolio
| Key Parameters | Description |
| Type of Products / Devices Offered |
|
| Application Area | Skin Tightening |
| Type of Procedure | Minimally Invasive |
| End User | Hospitals / Clinics / Medical Spas |
Further details on recent initiatives taken by PharmaResearch as well as other botox companies have been provided in detail in the report
Revance Therapeutics Injection DAXXIFY®, an Injectable Neuromodulator, Was Approved by the FDA in September 2022
5. Revance Therapeutics
Revance Therapeutics is a medical aesthetic solutions provider engaged in offering various treatments as well as services to improve the cosmetic appearance of its clients. The company’s aesthetics pipeline is comprised of botox and dermal fillers along with the development of other neuromodulators. In addition to aesthetic offerings, the firm is working in the domain of therapeutic offerings as well.
DAXXIFY® (DaxibotulinumtoxinA-lanm) injection is the first and only peptide formulated neuromodulator with long-lasting results for the temporary improvement of moderate to severe frown lines (glabellar lines) in adults. The similar injection is under phase II trial for other treatments namely forehead lines, lateral canthal lines and upper facial lines. Moreover, various other products are in the clinical pipeline and have shown promising results.
Revance Therapeutics: Company Overview
| Key Parameters | Description |
| Company Logo |  |
| Year of Establisment | 2002 |
| Number of Employees | 201-500 |
| Headquarter |  |
Revance Therapeutics: Medical Aesthetics Portfolio
| Key Parameters | Description |
| Type of Products / Devices Offered |
|
| Application Area | Skin Tightening |
| Type of Procedure | Minimally Invasive |
| End User |
|
Recent Developments:
In March 2024, Revance announced its plans to raise $100 million through an underwritten public offering, with the aim to use the funds for expanding the therapeutic applications and commercialization efforts on DAXXIFY.
Further details on recent initiatives taken by Revance Therapeutics as well as other botox companies have been provided in detail in the report.
What About the Other Botox Companies Around the World?
The above presentation features five top botox companies selected from a pool of around 25 players that we have compiled. If you're interested, you can download the Sample Report on this topic by Roots Analysis. For personalized assistance in identifying the most relevant solutions based on your specific criteria, please don't hesitate to reach out to us at sales@rootsanalysis.com.
Sources
- https://www.isaps.org/discover/about-isaps/global-statistics/reports-and-press-releases/global-survey-2021-full-report-and-press-releases/
- https://news.abbvie.com/2023-09-18-Allergan-Aesthetics-Announces-Positive-Topline-Results-from-Second-Phase-3-Study-of-OnabotulinumtoxinA-BOTOX-R-Cosmetic-for-the-Treatment-of-Platysma-Prominence
- https://www.pharmexec.com/view/fda-approves-hugel-america-s-letybo-to-treat-moderate-to-severe-frown-lines-in-adults
- https://www.ft.com/content/0dde3aa7-26cc-4e76-a02f-3ab51610952b
- https://investors.revance.com/investors/Press-Releases/news-details/2024/Revance-Announces-Pricing-of-100.0-Million-Public-Offering-of-Common-Stock/default.aspx